Santen Pharmaceutical Co., Ltd. Overview
Pro stress-test →Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products, operating globally with trailing twelve month revenue of ¥287,994 million. The company specializes in glaucoma treatments and has an extensive clinical pipeline targeting multiple eye disease indications.
Strategic Profile
Pro stress-test →Santen demonstrates improving margins with trailing net profit margin of 10.8% compared to 8.6% a year earlier, alongside 20.2% earnings growth over the last 12 months. The company faces modest 2.5% revenue growth forecast versus the broader JP market and relies on margin support for value creation, positioning it as a profitability-driven play rather than a growth story.
Competitive Landscape
Pro stress-test →Santen competes primarily in the global ophthalmic pharmaceutical market against major players like Allergan (AbbVie), Bausch + Lomb, and Sun Pharmaceutical. The company differentiates through its focused ophthalmic portfolio, particularly in glaucoma treatments where it holds established market positions, and its advancing pipeline for adjacent indications like myopia and dry eye. The therapeutic focus creates a defensible niche versus diversified pharma competitors.
Industry Context
Santen Pharmaceutical Co., Ltd. operates in Pharmaceutical Manufacturing - Ophthalmology.
Key facts
Founded: 1890 · Headquarters: Osaka, Japan · Revenue: ¥288.0B · Market cap: ¥553.6B (~$3.5B)